GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicine Man Technologies Inc (OTCPK:SHWZ) » Definitions » ROE %

Medicine Man Technologies (Medicine Man Technologies) ROE % : -57.54% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicine Man Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Medicine Man Technologies's annualized net income for the quarter that ended in Mar. 2024 was $-64.2 Mil. Medicine Man Technologies's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $111.6 Mil. Therefore, Medicine Man Technologies's annualized ROE % for the quarter that ended in Mar. 2024 was -57.54%.

The historical rank and industry rank for Medicine Man Technologies's ROE % or its related term are showing as below:

SHWZ' s ROE % Range Over the Past 10 Years
Min: -3706.33   Med: -20.69   Max: 23.09
Current: -25.43

During the past 10 years, Medicine Man Technologies's highest ROE % was 23.09%. The lowest was -3,706.33%. And the median was -20.69%.

SHWZ's ROE % is ranked worse than
79.52% of 996 companies
in the Drug Manufacturers industry
Industry Median: 4.26 vs SHWZ: -25.43

Medicine Man Technologies ROE % Historical Data

The historical data trend for Medicine Man Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicine Man Technologies ROE % Chart

Medicine Man Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.78 -56.81 16.56 -13.90 -27.48

Medicine Man Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.24 -18.73 -0.88 -88.62 -57.54

Competitive Comparison of Medicine Man Technologies's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Medicine Man Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicine Man Technologies's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicine Man Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where Medicine Man Technologies's ROE % falls into.



Medicine Man Technologies ROE % Calculation

Medicine Man Technologies's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-34.549/( (132.163+119.292)/ 2 )
=-34.549/125.7275
=-27.48 %

Medicine Man Technologies's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-64.212/( (119.292+103.88)/ 2 )
=-64.212/111.586
=-57.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Medicine Man Technologies  (OTCPK:SHWZ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-64.212/111.586
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-64.212 / 166.404)*(166.404 / 352.3755)*(352.3755 / 111.586)
=Net Margin %*Asset Turnover*Equity Multiplier
=-38.59 %*0.4722*3.1579
=ROA %*Equity Multiplier
=-18.22 %*3.1579
=-57.54 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-64.212/111.586
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-64.212 / -48.276) * (-48.276 / -10.836) * (-10.836 / 166.404) * (166.404 / 352.3755) * (352.3755 / 111.586)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.3301 * 4.4551 * -6.51 % * 0.4722 * 3.1579
=-57.54 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Medicine Man Technologies ROE % Related Terms

Thank you for viewing the detailed overview of Medicine Man Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicine Man Technologies (Medicine Man Technologies) Business Description

Traded in Other Exchanges
Address
4880 Havana Street, Suite 201, Denver, CO, USA, 80239
Medicine Man Technologies Inc is engaged in providing general consulting services in the cannabis industry. The company also provide seminar which includes giving guidance and tips on industry opportunities, medical and recreational market trends, cultivation methodologies and technology, extraction technology, dispensary operation, security requirements. The company's operating segment includes- Retail, consisting of retail locations for sale of cannabis products; Wholesale, consisting of manufacturing, cultivation and sale of both wholesale cannabis and non-cannabis products; Other, consisting of all other income and expenses. It generates maximum revenue from the Retail segment. The company is now operating under its new trade name, Schwazze.
Executives
Christine Jones officer: Chief Legal Officer C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA ST., SUITE 201, DENVER CO 80239
Forrest Hoffmaster officer: CFO C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA ST., SUITE 201, DENVER CO 80239
Nirup Krishnamurthy director, officer: President 4880 HAVANA STREET, SUITE 201, DENVER CO 80239
Kathy P Vrabeck director 625 WESTPORT PARKWAY, GRAPEVINE TX 76051
Jeff Garwood director 55 TABBY CIRCLE, DAUFUSKIE ISLAND SC 29915
Pratap Chandra Mukharji director 4880 HAVANA STREET, SUITE 201, DENVER CO 80239
Salim Husan Wahdan director 4880 HAVANA ST., STE. 201, DENVER CO 80239
Paul Joseph Montalbano director 4880 HAVANA ST., STE. 201, DENVER CO 80239
Brad Stewart director C/O SEMPER PARATUS ACQUISITION CORP., 767 THIRD AVENUE, 38TH FLOOR, NEW YORK NY 10017
Justin Dye director, 10 percent owner, officer: CEO C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA STREET, SUITE 201, DENVER CO 80239
Jeffrey Alley Cozad director, 10 percent owner C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA ST., SUITE 201, DENVER CO 80239
Crw Capital Holdings Ii, Llc 10 percent owner 4740 W. MOCKINGBIRD LANE, STE 195579, DALLAS TX 75209
Crw Capital, Llc 10 percent owner 4740 W. MOCKINGBIRD LANE, P.O. BOX 195579, DALLAS TX 75209
Crw Capital Cann Holdings, Llc 10 percent owner 4740 W. MOCKINGBIRD LANE, P.O. BOX 195579, DALLAS TX 75209
Brian Ruden 10 percent owner C/O 4880 HAVANA STREET, SUITE 102, DENVER CO 80239